Sweden's medtech market stable
This article was originally published in Clinica
Sweden's medtech market was worth an estimated $550 million in 1995, and the Swedes were among the world's highest per capita spenders at around $62. Domestic production has remained at around SKr 5,000 million ($725 million) since the late 1980s, but with the country's large producers committed to exports, Sweden has a positive trade balance in most sectors. In 1992, production fell by 1.6% due principally to a 36% decline in pacemaker production, says a Medistat country profile on Sweden.
You may also be interested in...
Oncology R&D isn’t waning, but investment in neurology and psychiatry drug development are paying off in new drug approvals. Rapid growth in CDER non-malignant hematology approvals reflects longer, broader trend toward orphan drugs.
We clean out your Martin Luther King Day inbox so you don't have to.
Political worries aside, industry is confidently executing on focused strategies as it welcomes a new decade, even if a lack of deal news at the J.P. Morgan Healthcare Conference didn't excite investors.